Clinical Trials Sponsored by AstraZeneca

Total 4278 results

AstraZeneca
AstraZeneca K.K.

Recruiting

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (FORTUNA)

Nonalcoholic Steatohepatitis

United States, China, Korea, Republic of, Germany, Japan, Spain, Vietnam, Argentina, Colombia, Peru, Brazil, Malaysia, Taiwan, Thailand, Italy, Turkey, Hong Kong, Singapore, India, Mexico, Chile, Philippines, Portugal
AstraZeneca
AstraZeneca K.K.

Recruiting

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia (PURSUIT)

Dyslipidemia

Denmark, Hungary, Spain, United States, Japan, Czechia, Slovakia, Canada
AstraZeneca

Not yet recruiting

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

Healthy Participants

United States
AstraZeneca

Recruiting

hATTR Polyneuropathy in Russia (PRIMER)

Hereditary Transthyretin Amyloidosis

Russian Federation
AstraZeneca

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis (OverTTuRe)

ATTR Amyloidosis

United Kingdom, United States, Denmark, Japan
AstraZeneca

Not yet recruiting

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. (MIRO-CKD)

Chronic Kidney Disease

United States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
AstraZeneca

Not yet recruiting

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

Uncontrolled Hypertension
AstraZeneca

Not yet recruiting

Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain. (ORESTES)

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Healthy Participants Study

United States
AstraZeneca

Recruiting

A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

Healthy Participants

Germany
AstraZeneca

Not yet recruiting

REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma (REACT-Asthma)

Asthma, Bronchial
AstraZeneca

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

COPD (Chronic Obstructive Pulmonary Disease)

France, Denmark, Italy, Spain, United States, Canada, Argentina, Japan, Colombia, Germany, Peru, Brazil, China, India, Thailand, Austria, Serbia, Malaysia, Philippines, Poland, Taiwan, Greece, Norway, Sweden, Mexico, Romania, Korea, Republic... and more
AstraZeneca

Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO)

Metastatic Prostate Cancer

United States, Australia
AstraZeneca

Recruiting

A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma (BREATH)

Asthma, Exercise-Induced

Russian Federation
AstraZeneca

Not yet recruiting

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA)

Lung Cancer

Thailand, Vietnam, Korea, Republic of, India, China, Taiwan, United States, Israel, Spain, Turkey
AstraZeneca

Recruiting

Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD (LOOP)

Non-Small Cell Lung Cancer

United States
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

Korea, Republic of, United Kingdom, Australia, United States, Spain
AstraZeneca

Recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
AstraZeneca

Recruiting

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Healthy Participants

United States
AstraZeneca

Not yet recruiting

NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients (iRetroBC)

HER2-negative
AstraZeneca

Recruiting

HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

Breast Cancer | Breast Neoplasms | Breast Carcinoma | Genes | HER2

Kuwait, Saudi Arabia, United Arab Emirates, Qatar
AstraZeneca

Recruiting

Non-alcoholic Steatohepatitis Registry Platform Study

NASH With Fibrosis

China
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Rheumatoid Arthritis

United Kingdom, Canada
AstraZeneca

Recruiting

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (ARTEMIDE-Bil01)

Biliary Tract Cancer

France, Spain, United Kingdom, United States, Italy, Korea, Republic of, Belgium, Canada, Germany, Brazil, China, India, Japan, Taiwan, Australia, Thailand, Hong Kong, Denmark, Turkey, Poland, Norway
AstraZeneca

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, Germany, China, Japan
AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

Denmark, Italy, Australia, Korea, Republic of, Belgium, United States, Canada, Japan, United Kingdom, China, Brazil, France, Taiwan, Spain, Norway, Switzerland, Turkey, Poland, Germany, South Africa, Netherlands
AstraZeneca

Recruiting

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

Chronic Kidney Disease With High Proteinuria

United Kingdom, Argentina, Italy, United States, Poland, Germany, Spain, Denmark, Sweden, France, China, Taiwan, Thailand, Vietnam, Brazil, Malaysia, Mexico, Philippines, Israel, Norway, Korea, Republic of, Canada, Japan, Turkey, Australia and more
AstraZeneca

Recruiting

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

Crohn's Disease

Sweden
AstraZeneca

Recruiting

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Hepatocellular Carcinoma (HCC)

United States
AstraZeneca

Not yet recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE)

Diffuse Large B-Cell Lymphoma
AstraZeneca

Recruiting

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

Mantle Cell Lymphoma (MCL)

Canada, Poland, United Kingdom, United States, Brazil, Spain, Australia
AstraZeneca

Recruiting

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) (DAISY)

Systemic Sclerosis | Scleroderma

United Kingdom, United States, Italy, Mexico, Belgium, Germany, Spain, China, France, India, Austria, Canada, Poland, Israel, Korea, Republic of, Hungary, Japan, South Africa, Turkey, Netherlands, Romania
AstraZeneca

Recruiting

A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation (OVARD)

Ovarian Cancer

Russian Federation
AstraZeneca

Recruiting

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Hepatic Impairment

United States
AstraZeneca

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Steatohepatitis

United States, Puerto Rico
AstraZeneca

Recruiting

Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol) (CHOROS ORION)

Chronic Obstructive Pulmonary Disease

Italy
AstraZeneca

Not yet recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants (SLE)

Systemic Lupus Erythematosus
AstraZeneca

Recruiting

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

Japan
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

China, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
AstraZeneca

Recruiting

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

Breast Cancer

Japan
AstraZeneca

Not yet recruiting

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs (EXCEED)

Pancreatic Cancer
AstraZeneca

Recruiting

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma (TREMENDOUS)

Hepatocellular Carcinoma

China
AstraZeneca

Recruiting

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction

Asthma

United States
AstraZeneca

Recruiting

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) (ZEAL)

Liver Cirrhosis

Spain, Denmark, Germany, United States, China, Australia, Belgium, Netherlands, Switzerland, Austria, Taiwan, Canada, Czechia
AstraZeneca

Recruiting

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia (NIS durvalumab)

NSCLC, Non-small-cell Lung Carcinoma

Russian Federation
AstraZeneca

Recruiting

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

Life Threatening Bleeding | Factor Xa Inhibitor

Japan
AstraZeneca

Recruiting

PASS of Paediatric Patients Initiating Selumetinib

Neurofibromatosis Type 1

Portugal, Spain, United Kingdom, Israel, France, Italy, Switzerland, Germany, Austria
AstraZeneca

Recruiting

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello280)

Prostate Cancer

United States, China, Israel, Korea, Republic of, Canada, Poland, Spain, Belgium, Hungary, Japan, United Kingdom, France, Brazil, Taiwan, Australia, Turkey, Chile, Czechia, India, Mexico, Netherlands, Greece
AstraZeneca

Recruiting

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study (CONTINUITY)

Chronic Kidney Disease | Hyperkalaemia

United Kingdom, Spain, Belgium, Italy, Netherlands, France, Germany
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

Non-Small Cell Lung Cancer

China, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine

3

Subscribe